The CXCR3(+)CD56Bright Phenotype Characterizes a Distinct NK Cell Subset with Anti-Fibrotic Potential That Shows Dys-Regulated Activity in Hepatitis C

Background In mouse models, natural killer (NK) cells have been shown to exert anti-fibrotic activity via killing of activated hepatic stellate cells (HSC). Chemokines and chemokine receptors critically modulate hepatic recruitment of NK cells. In hepatitis C, the chemokine receptor CXCR3 and its ligands have been shown to be associated with stage of fibrosis suggesting a role of these chemokines in HCV associated liver damage by yet incompletely understood mechanisms. Here, we analyzed phenotype and function of CXCR3 expressing NK cells in chronic hepatitis C. Methods Circulating NK cells from HCV-infected patients (n = 57) and healthy controls (n = 27) were analyzed with respect to CXCR3 and co-expression of different maturation markers. Degranulation and interferon-γ secretion of CXCR3(+) and CXCR3(−) NK cell subsets were studied after co-incubation with primary human hepatic stellate cells (HSC). In addition, intra-hepatic frequency of CXCR3(+) NK cells was correlated with stage of liver fibrosis (n = 15). Results We show that distinct NK cell subsets can be distinguished based on CXCR3 surface expression. In healthy controls CXCR3(+)CD56Bright NK cells displayed strongest activity against HSC. Chronic hepatitis C was associated with a significantly increased frequency of CXCR3(+)CD56Bright NK cells which showed impaired degranulation and impaired IFN-γ secretion in response to HSC. Of note, we observed intra-hepatic accumulation of this NK cell subset in advanced stages of liver fibrosis. Conclusion We show that distinct NK cell subsets can be distinguished based on CXCR3 surface expression. Intra-hepatic accumulation of the functionally impaired CXCR3(+)CD56Bright NK cell subset might be involved in HCV-induced liver fibrosis.

[1]  David L. Thomas,et al.  CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. , 2011, The Journal of infectious diseases.

[2]  F. Tacke,et al.  Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[3]  W. Jeong,et al.  Suppression of innate immunity (natural killer cell/interferon‐γ) in the advanced stages of liver fibrosis in mice , 2011, Hepatology.

[4]  A. Casrouge,et al.  Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. , 2011, The Journal of clinical investigation.

[5]  Céline Hernandez,et al.  Hepatitis C Virus (HCV) Evades NKG2D-Dependent NK Cell Responses through NS5A-Mediated Imbalance of Inflammatory Cytokines , 2010, PLoS pathogens.

[6]  S. Friedman,et al.  Amelioration of hepatic fibrosis by NK cell activation , 2010, Gut.

[7]  Marianthi Markatou,et al.  Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. , 2009, The Journal of infectious diseases.

[8]  G. Michelone,et al.  Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. , 2009, Gastroenterology.

[9]  C. Tinelli,et al.  Prospective study of natural killer cell phenotype in recurrent hepatitis C virus infection following liver transplantation. , 2009, Journal of hepatology.

[10]  L. Chiriboga,et al.  Intrahepatic levels of CXCR3‐associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C , 2008, Hepatology.

[11]  W. Jeong,et al.  Innate immunity and alcoholic liver fibrosis , 2008, Journal of gastroenterology and hepatology.

[12]  W. Jeong,et al.  Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. , 2008, Gastroenterology.

[13]  W. Jeong,et al.  Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis , 2007, Expert review of gastroenterology & hepatology.

[14]  W. Jeong,et al.  Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[15]  A. Neumann,et al.  IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection , 2006, Hepatology.

[16]  W. Jeong,et al.  STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity , 2006, Hepatology.

[17]  A. Neumann,et al.  Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. , 2006, The Journal of infectious diseases.

[18]  S. Friedman,et al.  Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. , 2006, Journal of hepatology.

[19]  References Subscriptions Permissions Email Alerts Cell-Dependent Liver Damage T Fas Ligand Is Responsible for CXCR3 Chemokine Induction in CD4 + , 2013 .

[20]  A. E. Yeo,et al.  Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing , 2006, Hepatology.

[21]  R. Sun,et al.  Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. , 2006, Gastroenterology.

[22]  M. Diago,et al.  Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C , 2005, Gut.

[23]  Andrew H Talal,et al.  Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. , 2005, Blood.

[24]  S. McColl,et al.  Expression of the CXCR3 ligand I‐TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation , 2004, Hepatology.

[25]  Rakesh K. Kumar,et al.  Expression of the chemokine IP‐10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation , 2003, Journal of leukocyte biology.

[26]  D. Doherty,et al.  Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. , 1998, Journal of hepatology.